Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.9K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

788
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
788
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

1.2K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.2K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

5.7K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of anti-Müllerian hormone and antral follicle count discordance on elective fertility preservation outcomes.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2026
Same author

Maternal SARS-CoV-2 infection and early child growth and development: A nationwide cohort study.

The Journal of infection·2026
Same author

Impact of ultrasound operator training on clinical pregnancy rates during embryo transfer: a retrospective cohort study.

Frontiers in reproductive health·2026
Same author

Clinical Outcomes of ICSI Using Advanced Quantitative Phase Microscopy.

Bioengineering (Basel, Switzerland)·2026
Same author

Autonomous biogenesis of all thirty proteins of the Escherichia coli translation machinery.

Nature communications·2025
Same author

SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic.

Pharmaceuticals (Basel, Switzerland)·2025
Same journal

Perinatal insights into human T-lymphotropic virus 1 in western French Guiana: Unmasking a silent disease.

European journal of obstetrics, gynecology, and reproductive biology·2026
Same journal

Sentinel lymph node biopsy in atypical endometrial hyperplasia: impact on staging and adjuvant treatment.

European journal of obstetrics, gynecology, and reproductive biology·2026
Same journal

Selective intraoperative multi-vessel embolization for placenta accreta spectrum: a doubly robust propensity-weighted analysis of a histologically confirmed cohort.

European journal of obstetrics, gynecology, and reproductive biology·2026
Same journal

Retraction notice to "Amino acid chelated iron versus an iron salt in the treatment of iron deficiency anemia with pregnancy: A randomized controlled study" [Eur. J. Obstet. Gynecol. Reprod. Biol. 210 (2017) 242-246].

European journal of obstetrics, gynecology, and reproductive biology·2026
Same journal

Fertility and pregnancy knowledge and expectations among women with a history of metabolic bariatric surgery.

European journal of obstetrics, gynecology, and reproductive biology·2026
Same journal

A prospective non-randomized controlled study of a flexible panoramic electronic hysteroscope in outpatient hysteroscopic diagnosis and treatment.

European journal of obstetrics, gynecology, and reproductive biology·2026
See all related articles

Related Experiment Video

Updated: Apr 18, 2026

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

8.1K

GnRH-antagonist programming versus GnRH agonist protocol: a randomized trial.

Anat Hershko Klement1, Arie Berkovitz1, Amir Wiser1

  • 1The IVF Unit, Department of Obstetrics and Gynecology, Meir Medical Center, 59 Tschernihovsky St., Kfar Saba 44299, Israel.

European Journal of Obstetrics, Gynecology, and Reproductive Biology
|January 17, 2015
PubMed
Summary
This summary is machine-generated.

This study shows that programming in vitro fertilization (IVF) gonadotropin-releasing hormone (GnRH) antagonist cycles can successfully avoid weekend oocyte retrieval without compromising outcomes. This approach offers flexibility in scheduling IVF procedures.

Keywords:
Drug administration scheduleIn vitro fertilizationOocyte retrievalPatient schedulePituitary hormone release inhibiting hormones

More Related Videos

Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management
03:53

Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management

Published on: March 15, 2024

3.3K
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.8K

Related Experiment Videos

Last Updated: Apr 18, 2026

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

8.1K
Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management
03:53

Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management

Published on: March 15, 2024

3.3K
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.8K

Area of Science:

  • Reproductive Endocrinology
  • In Vitro Fertilization (IVF)

Background:

  • Weekend oocyte retrieval in IVF can pose logistical challenges.
  • Gonadotropin-releasing hormone (GnRH) antagonist protocols offer flexibility in cycle management.

Purpose of the Study:

  • To evaluate the efficacy of programming GnRH antagonist cycles to avoid weekend oocyte retrieval.
  • To assess if programmed follicular estrogen can be used in GnRH antagonist protocols.

Main Methods:

  • A preliminary randomized clinical trial compared a programmed GnRH antagonist protocol with a standard GnRH agonist protocol.
  • Patients received estradiol valerate to facilitate Friday follicular development and subsequent stimulation.

Main Results:

  • No significant differences in cycle dynamics, oocyte yield, fertilization, embryo quality, or pregnancy rates were observed.
  • Only one patient in the treatment group required weekend oocyte retrieval.
  • A significant difference was noted in the number of follicles ≥18 mm on hCG administration day.

Conclusions:

  • Follicular estrogen programming in GnRH antagonist cycles is feasible and does not negatively impact IVF outcomes.
  • This strategy provides reassurance for achieving scheduling goals and avoiding weekend retrievals.